Summit Therapeutics (SMMT) News Today $24.39 +0.38 (+1.58%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SMMT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Tema Etfs LLC Purchases New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT)Tema Etfs LLC purchased a new stake in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 26,641 shares of the company's stock, valued at approxiMay 20 at 6:23 AM | marketbeat.comRafferty Asset Management LLC Has $5.56 Million Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)Rafferty Asset Management LLC increased its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 187.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 311,692 shares of the company's stock after acqMay 20 at 5:39 AM | marketbeat.comDeutsche Bank AG Has $8.55 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT)Deutsche Bank AG lifted its holdings in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 20.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 478,808 shares of the company's stock after buying an additional 81,130 sharMay 19 at 3:57 AM | marketbeat.comGot $100? 3 Top Growth Stocks to Buy That Could Double Your MoneyMay 18 at 5:47 AM | fool.comJefferies Financial Group Inc. Acquires Shares of 45,001 Summit Therapeutics Inc. (NASDAQ:SMMT)Jefferies Financial Group Inc. bought a new stake in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 45,001 shares of the company's stock, valued aMay 18 at 4:34 AM | marketbeat.comNorthern Trust Corp Has $15.55 Million Position in Summit Therapeutics Inc. (NASDAQ:SMMT)Northern Trust Corp raised its position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 1.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 871,402 shares of the company's stock afterMay 17, 2025 | marketbeat.comDimensional Fund Advisors LP Acquires 160,592 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)Dimensional Fund Advisors LP boosted its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 358.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 205,337 shares of the company's stock after aMay 16, 2025 | marketbeat.comStockNews.com Upgrades Summit Therapeutics (NASDAQ:SMMT) to "Hold"StockNews.com upgraded shares of Summit Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday.May 15, 2025 | marketbeat.comBNP Paribas Financial Markets Invests $8.80 Million in Summit Therapeutics Inc. (NASDAQ:SMMT)BNP Paribas Financial Markets purchased a new position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 493,189 shares of the company'sMay 14, 2025 | marketbeat.comHsbc Holdings PLC Invests $188,000 in Summit Therapeutics Inc. (NASDAQ:SMMT)Hsbc Holdings PLC acquired a new position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 10,700 shares of the company's stock, valued at aMay 13, 2025 | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Receives $37.40 Average Target Price from BrokeragesMay 13, 2025 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Raised to "Strong-Buy" at TD CowenTD Cowen raised shares of Summit Therapeutics to a "strong-buy" rating in a report on Thursday.May 12, 2025 | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Receives Average Rating of "Buy" from AnalystsShares of Summit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) have earned a consensus recommendation of "Buy" from the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation. The averageMay 12, 2025 | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Shares Sold by Balyasny Asset Management L.P.Balyasny Asset Management L.P. reduced its position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 10.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 387,242 shares of the company's stockMay 12, 2025 | marketbeat.comSummit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term GainMay 9, 2025 | insidermonkey.comSummit Therapeutics Inc. (NASDAQ:SMMT) Shares Sold by Bosun Asset Management LLCBosun Asset Management LLC lowered its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 41.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 15,344 shares of the company's stock after selling 10,943 shares during the quaMay 9, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Purchases 181,185 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)The Manufacturers Life Insurance Company grew its position in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 61.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 476,814 shares of the company's stock after purchasing an additiMay 8, 2025 | marketbeat.comCan Summit Therapeutics Stock Double Your Money?May 7, 2025 | finance.yahoo.comBayesian Capital Management LP Invests $1.20 Million in Summit Therapeutics Inc. (NASDAQ:SMMT)Bayesian Capital Management LP acquired a new position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 67,039 shares of the company's stoMay 7, 2025 | marketbeat.comBellevue Group AG Has $3.04 Million Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)Bellevue Group AG increased its position in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 130.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 170,594 shares of the company's stock after purMay 6, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Issues Quarterly Earnings ResultsSummit Therapeutics (NASDAQ:SMMT - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01.May 5, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Issues Earnings ResultsSummit Therapeutics (NASDAQ:SMMT - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01.May 5, 2025 | marketbeat.comTower Research Capital LLC TRC Raises Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT)Tower Research Capital LLC TRC grew its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 1,032.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,936 shares of the company's stock after purchasing an additional 15,44May 5, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Trading 16.9% Higher After Better-Than-Expected EarningsSummit Therapeutics (NASDAQ:SMMT) Trading Up 16.9% Following Strong EarningsMay 4, 2025 | marketbeat.com250,000 Shares in Summit Therapeutics Inc. (NASDAQ:SMMT) Acquired by Boxer Capital Management LLCBoxer Capital Management LLC purchased a new position in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 250,000 shares of the company's stock, valuedMay 4, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Makes New $1.20 Million Investment in Summit Therapeutics Inc. (NASDAQ:SMMT)Susquehanna Fundamental Investments LLC bought a new stake in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 67,378 shares of the compaMay 4, 2025 | marketbeat.comQ2 EPS Forecast for Summit Therapeutics Reduced by AnalystSummit Therapeutics Inc. (NASDAQ:SMMT - Free Report) - HC Wainwright cut their Q2 2025 earnings per share estimates for Summit Therapeutics in a report issued on Monday, April 28th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.10) per share for the quarMay 3, 2025 | marketbeat.comThis Soaring Stock Just Delivered More Good News. Time to Buy?May 2, 2025 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025May 1, 2025 | businesswire.comSummit Therapeutics (NasdaqGM:SMMT) Sees 16% Stock Price Increase Over Past MonthApril 30, 2025 | finance.yahoo.comSummit Therapeutics (NASDAQ:SMMT) Sees Unusually-High Trading Volume - What's Next?Summit Therapeutics (NASDAQ:SMMT) Sees Strong Trading Volume - What's Next?April 30, 2025 | marketbeat.comJMP Securities Reiterates "Market Outperform" Rating for Summit Therapeutics (NASDAQ:SMMT)JMP Securities reaffirmed a "market outperform" rating and set a $40.00 target price on shares of Summit Therapeutics in a report on Monday.April 30, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Has $117 Million Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)Price T Rowe Associates Inc. MD raised its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 20.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,557,927 shares of the company's stock after buying an aApril 30, 2025 | marketbeat.comWhy Is Summit Therapeutics Stock Trading Higher On Monday?April 28, 2025 | benzinga.comThree Seasons Wealth LLC Acquires New Position in Summit Therapeutics Inc. (NASDAQ:SMMT)Three Seasons Wealth LLC bought a new position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 12,869 shares of the company's stock, valued at approximately $230,000. AApril 28, 2025 | marketbeat.comBarclays PLC Has $5.89 Million Position in Summit Therapeutics Inc. (NASDAQ:SMMT)Barclays PLC raised its stake in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 32.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 330,146 shares of the company's stock after acquiring an adApril 28, 2025 | marketbeat.comWells Fargo & Company MN Raises Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)Wells Fargo & Company MN increased its stake in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 79.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,265 shares of the cApril 28, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Should You Sell?Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's What HappenedApril 27, 2025 | marketbeat.comAkeso survival data for ivonescimab misses expectations, STAT saysApril 27, 2025 | finance.yahoo.comInvesco Ltd. Acquires 324,555 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)Invesco Ltd. raised its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 435.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 399,050 shares of the company's stock after acquiring an additional 324,555 shares during the quarteApril 27, 2025 | marketbeat.comGuggenheim Capital LLC Makes New Investment in Summit Therapeutics Inc. (NASDAQ:SMMT)Guggenheim Capital LLC purchased a new position in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 42,887 shares of the company's stock, valued at approximatelyApril 26, 2025 | marketbeat.comJPMorgan Chase & Co. Sells 23,068 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)JPMorgan Chase & Co. trimmed its stake in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 14.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 139,581 shares of the company's stock after selling 23,068 sharesApril 26, 2025 | marketbeat.comWhy Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged TodayApril 25, 2025 | fool.comWhat's Going On With Summit Therapeutics Stock On Friday?April 25, 2025 | benzinga.comInterim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in ChinaApril 25, 2025 | businesswire.comSummit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025April 24, 2025 | businesswire.comSummit Therapeutics (SMMT) to Release Quarterly Earnings on TuesdaySummit Therapeutics (NASDAQ:SMMT) will be releasing its Q1 2025 earnings on Tuesday, April 29. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-4-29-summit-therapeutics-inc-stock/)April 24, 2025 | marketbeat.comWhy Summit Therapeutics Rocketed Double-Digits TodayApril 23, 2025 | fool.comWhy Is Summit Therapeutics Stock Soaring On Wednesday?April 23, 2025 | benzinga.comSummit Therapeutics Inc. (NASDAQ:SMMT) Shares Purchased by Rock Springs Capital Management LPRock Springs Capital Management LP grew its stake in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 1.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,054,000 shares of the companyApril 23, 2025 | marketbeat.com Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Videos SMMT Media Mentions By Week SMMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SMMT News Sentiment▼1.420.65▲Average Medical News Sentiment SMMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SMMT Articles This Week▼97▲SMMT Articles Average Week Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today argenx News Today BioNTech News Today Beigene News Today Teva Pharmaceutical Industries News Today Intra-Cellular Therapies News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Viatris News Today Moderna News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SMMT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SMMT Stock Free SMMT Stock Alerts